Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

"We finished 2025 on a strong note by delivering results that were solidly ahead of our expectations," said Prahlad Singh, president and chief executive officer of Revvity. "Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come."

Financial Overview by Reporting Segment for the Fourth Quarter and Full Year 2025

Life Sciences

• Fourth quarter 2025 revenue was $382 million, as compared to $375 million in the same period a year ago. Revenue increased 2% and organic revenue was flat as compared to the same period a year ago.
• Full year 2025 revenue was $1,431 million, as compared to $1,399 million in 2024. Revenue increased 2% and organic revenue increased 2% as compared to the same period a year ago.
• Fourth quarter 2025 adjusted operating income was $136 million, as compared to $138 million in the same period a year ago. Adjusted operating profit margin was 35.6% as a percentage of revenue, as compared to 36.9% in the same period a year ago.
• Full year 2025 adjusted operating income was $458 million, as compared to $467 million in 2024. Adjusted operating profit margin was 32.0% as a percentage of revenue, as compared to 33.4% in 2024.

Diagnostics

• Fourth quarter 2025 revenue was $390 million, as compared to $355 million in the same period a year ago. Revenue increased 10% and organic revenue increased 7% as compared to the same period a year ago.
• Full year 2025 revenue was $1,425 million, as compared to $1,356 million in 2024. Revenue increased 5% and organic revenue increased 4% as compared to the same period a year ago.
• Fourth quarter 2025 adjusted operating income was $91 million, as compared to $91 million in the same period a year ago. Adjusted operating profit margin was 23.4% as a percentage of revenue, as compared to 25.7% in the same period a year ago.
• Full year 2025 adjusted operating income was $344 million, as compared to $354 million in 2024. Adjusted operating profit margin was 24.2% as a percentage of revenue, as compared to 26.1% in 2024.

Initiates Full Year 2026 Guidance

For the full year 2026, the Company forecasts total revenue of $2.96-$2.99 billion, organic revenue growth of 2-3%, and adjusted earnings per share of $5.35-$5.45.

Guidance for the full year 2026 for organic revenue growth and adjusted EPS is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company’s results prepared in accordance with GAAP.

Webcast Information

The Company will discuss its fourth quarter and full year 2025 results and its outlook for business trends during a webcast on February 2, 2026, at 8:00 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the Company’s website, ir.revvity.com.

Use of Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as “believes”, “intends”, “anticipates”, “plans”, “expects”, “estimates”, “projects”, “forecasts”, “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments, including as the result of recently implemented and recently threatened tariff increases; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and divestitures, license technologies, or to successfully integrate acquired businesses or licensed technologies into our existing businesses or to make them profitable; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (8) disruptions in the supply of raw materials and supplies; (9) our ability to retain key personnel; (10) significant disruption in our information technology systems, or cybercrime; (11) our ability to realize the full value of our intangible assets; (12) our failure to adequately protect our intellectual property; (13) the loss of any of our licenses or licensed rights; (14) the manufacture and sale of products exposing us to product liability claims; (15) our failure to maintain compliance with applicable government regulations; (16) our failure to comply with data privacy and information security laws and regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) our ability to obtain future financing; (21) restrictions in our credit agreements; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.